The tragic history of AIDS in the hemophilia population, 1982–1984

Evatt, Bruce L.

doi:10.1111/j.1538-7836.2006.02213.x

Cited by 79 publications

(76 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result of the catastrophic HIV-contamination of factor products in the early 1980s, the majority of severe hemophiliacs died as a result of AIDS resulting in a small number of adults with inhibitors for the past 20 years [7]. In 1985, testing of factor for HIV and subsequently development of first virally inactivated and then recombinant factor concentrates has essentially eliminated this threat.…”

Section: Introductionmentioning

confidence: 98%

Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population

Young

2010

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

The major adverse effect of factor replacement therapy in patients with hemophilia is the development of neutralizing antibodies termed inhibitors. This complication renders standard factor replacement therapy ineffective resulting in increased morbidity and mortality. Until recently, the population of adults with inhibitors was relatively small due to the death of many of the patients from HIV that they contracted from contaminated factor in the early 1980s. With the advent of factor products with reduced risks for deadly infections in the mid-1980s to early 1990s, a cohort of inhibitor patients is now beginning to enter adulthood thus raising the issues regarding the transition of these patients into adulthood. It is, therefore, expected that adult hematologists will be seeing more inhibitor patients and that pediatric hematologists will be faced with managing this transition process, which may not necessarily include transition to an adult facility or adult hematologist. This review will discuss the various issues ranging from choice of medical provider to a discussion of psychosocial and financial issues facing this specific patient population.

show abstract

Section: Introductionmentioning

confidence: 98%

Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population

Young

2010

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…2 The oldest generation of men with hemophilia in the United States experienced childhood with no or little availability of clotting factor replacement. As the first lyophilized therapies became broadly available in the early 1970s, home infusion therapy became possible, allowing rapid on-demand treatment of hemorrhage and, subsequently, prophylactic factor replacement.…”

Section: Introductionmentioning

confidence: 99%

Men with severe hemophilia in the United States: birth cohort analysis of a large national database

Mazepa¹,

Monahan

Baker

et al. 2016

Blood

102

130

View full text Add to dashboard Cite

show abstract

“…In 1982 the first US haemophilic patient was reported as being infected with the Human Immunodeficiency Virus (HIV) [6]; this new discovery raised concern and led to further report of additional cases; HIV reached incidence rates of 60 cases per million in 1990 in the US and one case in every seven people in the UK among haemophilic population [6,7]. HIV accounted for a quarter of all causes of death in this population during the 1990s in Netherlands [8,9].…”

Section: Introductionmentioning

confidence: 99%

“…It has been estimated that 80 % of all deaths from the Acquired Immunodeficiency Syndrome (AIDS) occurred before 1995. It was only after the mid 1990s with the introduction of antiretroviral therapy (ARVT) that HIV related mortality in the haemophilic patients dropped [10], a Canadian study that monitored all causes of death in haemophilic patients between 1982 and 2003 (n = 2427) showed a reduction in mortality rates due to HIV from 74.6 % during 1982-1997 to 42.9 % after ARVT introduction [6,11]. By 1992 an estimated of 60 % of the US haemophilic patients, and 80 % of all patients ever treated with clotting factor concentrates were already infected with hepatitis C [12,13].…”

Section: Introductionmentioning

confidence: 99%

The History and Evolution of the Clinical Effectiveness of Haemophilia Type A Treatment: A Systematic Review

Castro

Briceño

Casas

et al. 2012

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

First evidence of cases of haemophilia dates from ancient Egypt, but it was when Queen Victoria from England in the 19th century transmitted this illness to her descendants, when it became known as the ''royal disease''. Last decades of the 20th century account for major discoveries that improved the life expectancy and quality of life of these patients. The history and evolution of haemophilia healthcare counts ups and downs. The introduction of prophylactic schemes during the 1970s have proved to be more effective that the classic on-demand replacement of clotting factors, nevertheless many patients managed with frequent plasma transfusions or derived products became infected with the Human Immunodeficiency Virus (HIV) and Hepatitis C virus during the 1980s and 1990s. Recombinant factor VIII inception has decreased the risk of blood borne infections and restored back longer life expectancies. Main concerns for haemophilia healthcare are shifting from the pure clinical aspects to the economic considerations of long-term replacement therapy. Nowadays researchers' attention has been placed on the future costs and cost-effectiveness of costly long-term treatment. Equity considerations are relevant as well, and alternative options for less affluent countries are under the scope of further research. The aim of this review was to assess the evidence of different treatment options for haemophilia type A over the past four decades, focusing on the most important technological advances that have influenced the natural course of this ''royal disease''.

show abstract

The tragic history of AIDS in the hemophilia population, 1982–1984

Cited by 79 publications

References 18 publications

Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population

Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population

Men with severe hemophilia in the United States: birth cohort analysis of a large national database

The History and Evolution of the Clinical Effectiveness of Haemophilia Type A Treatment: A Systematic Review

Contact Info

Product

Resources

About